{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pahlevan Kakhki M"],"funding":["European Research Council","NINDS NIH HHS","Agence Nationale de la Recherche (French National Research Agency)"],"pagination":["6419"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11289459"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Multiple Sclerosis (MS) is a heterogeneous inflammatory and neurodegenerative disease with an unpredictable course towards progressive disability. Treating progressive MS is challenging due to limited insights into the underlying mechanisms. We examined the molecular changes associated with primary progressive MS (PPMS) using a cross-tissue (blood and post-mortem brain) and multilayered data (genetic, epigenetic, transcriptomic) from independent cohorts. In PPMS, we found hypermethylation of the 1q21.1 locus, controlled by PPMS-specific genetic variations and influencing the expression of proximal genes (CHD1L, PRKAB2) in the brain. Evidence from reporter assay and CRISPR/dCas9 experiments supports a causal link between methylation and expression and correlation network analysis further im"],"journal":["Nature communications"],"pubmed_title":["A genetic-epigenetic interplay at 1q21.1 locus underlies CHD1L-mediated vulnerability to primary progressive multiple sclerosis."],"pmcid":["PMC11289459"],"funding_grant_id":["JCJC ANR-17-CE12-0006","818170","R35 NS111604"],"pubmed_authors":["Giordano A","Kular L","Filippi M","Boddul S","Samudyata S","Liu Y","Olsson T","Harroud A","Jagodic M","Esposito F","Starvaggi Cucuzza C","Lemee MV","James T","Hillert J","Gustafsson M","Wermeling F","Venkata S Badam T","Sorosina M","Golzio C","Gkogka A","Casaccia P","Shchetynsky K","Sellgren CM","Gyllenberg A","Pahlevan Kakhki M","Kockum I","Stridh P"],"additional_accession":[]},"is_claimable":false,"name":"A genetic-epigenetic interplay at 1q21.1 locus underlies CHD1L-mediated vulnerability to primary progressive multiple sclerosis.","description":"Multiple Sclerosis (MS) is a heterogeneous inflammatory and neurodegenerative disease with an unpredictable course towards progressive disability. Treating progressive MS is challenging due to limited insights into the underlying mechanisms. We examined the molecular changes associated with primary progressive MS (PPMS) using a cross-tissue (blood and post-mortem brain) and multilayered data (genetic, epigenetic, transcriptomic) from independent cohorts. In PPMS, we found hypermethylation of the 1q21.1 locus, controlled by PPMS-specific genetic variations and influencing the expression of proximal genes (CHD1L, PRKAB2) in the brain. Evidence from reporter assay and CRISPR/dCas9 experiments supports a causal link between methylation and expression and correlation network analysis further im","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-01T16:19:44.269Z","creation":"2025-04-19T07:03:28.5Z"},"accession":"S-EPMC11289459","cross_references":{"pubmed":["39079955"],"doi":["10.1038/s41467-024-50794-z"]}}